CHALLENGES IN THE TREATMENT OF INDIVIDUALS WITH TOURETTE SYNDROME: AN INTEGRATIVE REVIEW

Authors

  • Daniel Marinho Dantas Centro Universitário de Patos
  • Rodolfo de Melo Porto

DOI:

https://doi.org/10.56083/RCV2N3-011

Abstract

INTRODUCTION. tics disorders affect children, adolescents, and adults worldwide, representing only one of the many disorders included in tic disorders. The therapeutic approach requires a multiprofessional approach. It is necessary to evaluate the tics, determining the problems that may be associated with them, as well as the probable damage. Thus, the first step in the treatment is patient education by the family and/or school, since these are the first environments the individuals will be present in during the natural course of the syndrome's evolution. Among the medications, we have the adrenergic agents such as clonidine and guanfacine, which correspond to the first line for ST. Another type of medication are neuroleptics, which have a reduction effect of up to 70% of the tics, differentiating among themselves based on their side effect profiles. OBJECTIVE. To understand the challenges in treating the individual with Tourette Syndrome. METHODS. An integrative literature review was carried out by searching the PUBMED, BVS and SCIELO databases. Health science descriptors (DeCs) "Tourette Syndrome", "Drug Therapy" and "Treatment Outcome" associated with each other were selected for the search in the databases. In addition, the selected articles had a time frame between 2018 and 2021 in Portuguese, English, and Spanish. Furthermore, studies were read beforehand to exclude those that did not meet the selected research objectives, as well as duplicate articles. RESULTS AND DISCUSSION. It was noted that, among the treatments used, antipsychotics still continue to be the most used therapy for this illness, being the one with the most studies (40%). Besides these, the alpha agonists, with 20% of the articles, also showed their relevance and significant results in the treatment of ST. Alternative therapies have also been studied for ST, such as cannabinoids, appearing in 30% of the studies and botulinum toxin (20%), showing a beneficial effect on symptoms, but with little knowledge about the long-term therapeutic effects, as well as its possible adverse effects. CONCLUSION. It was noted that there are effective medications available for use, such as antipsychotics and alpha agonists; however, due to their burden of accompanying adverse effects, compliance is often difficult for patients and family members. Thus, it is necessary to actively search for new types of drug therapy for the syndrome, since there are therapies with more accessible side effect profiles and with similar or even better results.

References

ARTUKOGLU, B. B.; BLOCH, M. H. The potential of cannabinoid-based treatments in Tourette syndrome. CNS drugs, v. 33, n. 5, p. 417-430, 2019. DOI: https://doi.org/10.1007/s40263-019-00627-1

CHEN, C. et al. The association between tic medication therapy and psychiatric comorbidities among patients with Tourette syndrome: a national population-based study in Taiwan. Brain and Development, v. 42, n. 5, p. 373-382, 2020. DOI: https://doi.org/10.1016/j.braindev.2020.01.002

COFFEY, B. et al. Efficacy and safety of fixed-dose deutetrabenazine in children and adolescents for tics associated with Tourette syndrome: a randomized clinical trial. JAMA network open, v. 4, n. 10, p. e2129397-e2129397, 2021. DOI: https://doi.org/10.1001/jamanetworkopen.2021.29397

COX, J. H.; CAVANNA, A. E. Aripiprazole for the treatment of Tourette syndrome. Expert review of neurotherapeutics, v. 21, n. 4, p. 381-391, 2021. DOI: https://doi.org/10.1080/14737175.2021.1893693

DEEB, W.; MALATY, I. A.; MATHEWS, C. A. Tourette disorder and other tic disorders. Handbook of clinical neurology, v. 165, p. 123-153, 2019. DOI: https://doi.org/10.1016/B978-0-444-64012-3.00008-3

EFRON, D.; DALE, R. C. Tics and Tourette syndrome. Journal of paediatrics and child health, v. 54, n. 10, p. 1148-1153, 2018. DOI: https://doi.org/10.1111/jpc.14165

JANKOVIC, J. et al. Safety and efficacy of flexible-dose deutetrabenazine in children and adolescents with Tourette syndrome: a randomized clinical trial. JAMA network open, v. 4, n. 10, p. e2128204-e2128204, 2021. DOI: https://doi.org/10.1001/jamanetworkopen.2021.28204

KOHLI, N.; BLITZER, A. Botulinum Toxin for the Treatment of Motor and Phonic Tics: A Case Report. Annals of Otology, Rhinology & Laryngology, v. 129, n. 6, p. 625-627, 2020. DOI: https://doi.org/10.1177/0003489419898211

MÁRMORA, C. H. C. et al. Atualizações neurocientíficas na Síndrome de Tourette: uma revisão integrativa. Ciências & Cognição, v. 21, n. 02, p. 242-254, 2016.

NAGUY, A.; ADEL, T.; ALMAZEEDI, I. Paliperidone Use in Child Psychiatry: Evidence or Diffidence? Pharmacology, v. 104, n. 1-2, p. 67-70, 2019. DOI: https://doi.org/10.1159/000500629

PANDEY, S.; DASH, D. Progress in pharmacological and surgical management of Tourette syndrome and other chronic tic disorders. The Neurologist, v. 24, n. 3, p. 93-108, 2019. DOI: https://doi.org/10.1097/NRL.0000000000000218

SANTOS, P. R. B. Síndrome de Tourette e sua associação com Transtorno Obsessivo-Compulsivo (TOC), 2015.

SINGER, H. S. Tics and Tourette syndrome. Continuum: Lifelong Learning in Neurology, v. 25, n. 4, p. 936-958, 2019. DOI: https://doi.org/10.1212/CON.0000000000000752

SOUZA, M. T.; SILVA, M. D.; CARVALHO, R. Revisão integrativa: o que é e como fazer. Einstein (São Paulo), v. 8, p. 102-106, 2010. DOI: https://doi.org/10.1590/s1679-45082010rw1134

STERN, J. S. Tourette’s syndrome and its borderland. Practical neurology, v. 18, n. 4, p. 262-270, 2018. DOI: https://doi.org/10.1136/practneurol-2017-001755

TEIXEIRA, L. L. C. et al. Síndrome de La Tourette: revisão de literatura. Arquivos Internacionais de Otorrinolaringologia, v. 15, n. 4, p. 492-500, 2011. DOI: https://doi.org/10.1590/S1809-48722011000400014

THALER, A. et al. Single center experience with medical cannabis in Gilles de la Tourette syndrome. Parkinsonism & related disorders, v. 61, p. 211-213, 2019. DOI: https://doi.org/10.1016/j.parkreldis.2018.10.004

WANG, D. et al. Effects of Jian-Pi-Zhi-Dong Decoction on the Expression of 5-HT and Its Receptor in a Rat Model of Tourette Syndrome and Comorbid Anxiety. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research, v. 26, p. e924658-1, 2020. DOI: https://doi.org/10.12659/MSM.924658

Published

2022-05-27

How to Cite

Dantas, D. M. ., & Porto, R. de M. (2022). CHALLENGES IN THE TREATMENT OF INDIVIDUALS WITH TOURETTE SYNDROME: AN INTEGRATIVE REVIEW. Revista Contemporânea, 2(3), 228–245. https://doi.org/10.56083/RCV2N3-011

Issue

Section

Articles